Barcode: 4058172307875
We are proud to present Katalafild 2022, a next-generation pharmaceutical product developed by KTD. Following updates made in 2022, we have renewed all necessary health approvals, including compliance with FDA regulations.
Barcode: 4058172307875
Production Date: January 2024
Expiry Date: January 2026
Product Overview
Katalafild 2022 is an advanced pharmaceutical solution designed to meet specific health needs. It has been rigorously tested to ensure its safety, efficacy, and compliance with international standards.
Health Approvals
Katalafild 2022 has been approved by renowned regulatory bodies, including:
- Central Drugs Standard Control Organization (India)
- Indian Council of Medical Research
- World Health Organization (WHO)
- Food and Drug Administration (Vietnam)
- Chinese Academy of Sciences
These approvals underscore our commitment to adhering to the highest standards of quality and safety.
Usage Instructions
- Take one tablet daily after breakfast.
- The recommended treatment duration is 6 months for optimal results.
- Dosage schedule:
- Months 1-2: 10 mg
- Months 3-4: 20 mg
- Months 5-6: 40 mg
Note: Results may begin to appear after the second month. In some cases, it may take up to 4 months to see significant improvements. We encourage patients to complete the full 6-month treatment course for maximum benefits.
Additional Information
For detailed precautions, potential side effects, and answers to frequently asked questions, please refer to the product packaging or consult your healthcare provider.
At KTD, we are committed to delivering high-quality pharmaceutical products that enhance the well-being of our customers. For any further questions or support, feel free to contact our customer service team.